Takeda Pharmaceutical (NYSE:TAK) Insider Lauren Rusckowski Duprey Sells 47,586 Shares

Posted by Francis Steltz on Aug 13th, 2026

Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) insider Lauren Rusckowski Duprey sold 47,586 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $813,720.60. Following the sale, the insider owned 226,057 shares of the company’s stock, valued at approximately $3,865,574.70. The trade was a 17.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $17.42 on Thursday. The business’s 50-day simple moving average is $16.49 and its 200 day simple moving average is $17.13. The stock has a market cap of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion during the quarter. As a group, research analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TAK shares. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold”.

Check Out Our Latest Report on TAK

Key Stories Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing
Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Valeo Financial Advisors LLC increased its position in shares of Takeda Pharmaceutical by 6.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock worth $175,000 after acquiring an additional 632 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Takeda Pharmaceutical by 3.8% during the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares during the period. Abel Hall LLC lifted its position in Takeda Pharmaceutical by 2.3% in the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock valued at $632,000 after acquiring an additional 781 shares in the last quarter. Private Trust Co. NA lifted its position in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares in the last quarter. Finally, Checchi Capital Advisers LLC boosted its stake in Takeda Pharmaceutical by 5.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock worth $270,000 after purchasing an additional 786 shares during the period. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

(Get Free Report)

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.